TA
UTHR icon

TFB Advisors’s United Therapeutics UTHR Stock Holding History

TFB Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
2,279
-18
-0.8% -$10.1K 0.54% 42
2026
Q1 		$1.36M Sell
2,297
-419
-15% -$209K 0.71% 32
2025
Q4 		$1.32M Sell
2,716
-167
-6% -$77.8K 0.37% 61
2025
Q3 		$1.25M Sell
2,883
-1,138
-28% -$383K 0.36% 61
2025
Q2 		$1.16M Buy
4,021
+975
+32% +$291K 0.3% 75
2025
Q1 		$939K Buy
3,046
+784
+35% +$269K 0.27% 86
2024
Q4 		$798K Sell
2,262
-29
-1% -$10.7K 0.23% 100
2024
Q3 		$821K Buy
2,291
+376
+20% +$127K 0.24% 97
2024
Q2 		$610K Buy
1,915
+6
+0.3% +$1.59K 0.2% 112
2024
Q1 		$487K Buy
1,909
+896
+88% +$202K 0.18% 128
2023
Q4 		$223K Sell
1,013
-852
-46% -$196K 0.11% 157
2023
Q3 		$421K Sell
1,865
-89
-5% -$20.5K 0.51% 55
2023
Q2 		$431K Buy
1,954
+431
+28% +$95.5K 0.19% 127
2023
Q1 		$341K Buy
1,523
+263
+21% +$64.8K 0.26% 78
2022
Q4 		$350K Buy
+1,260
New +$318K 0.29% 70

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

TFB Advisors's UTHR Position: Q2 2026 in Review

TFB Advisors reduced its United Therapeutics (UTHR) stake by 0.78% in Q2 2026, selling an estimated $10.1K and leaving 2,279 shares worth $1.23M. The position accounts for 0.54% of the portfolio, ranked #42.

TFB Advisors first reported a position in UTHR in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.36M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • TFB Advisors held 2,279 shares of United Therapeutics worth $1.23M as of Q2 2026.
  • TFB Advisors sold 18 United Therapeutics shares in Q2 2026, an estimated $10.1K.
  • United Therapeutics made up 0.54% of TFB Advisors's portfolio in Q2 2026, its #42 holding.
  • TFB Advisors first reported a position in United Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • TFB Advisors's United Therapeutics position peaked at $1.36M in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on TFB Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.